We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.50 | -10.42% | 21.50 | 21.00 | 22.00 | 24.00 | 21.50 | 24.00 | 247,284 | 15:19:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Services, Nec | 3.4M | -46.22M | -0.4626 | -0.46 | 21.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/4/2021 10:48 | It's tough to pick a highlight from the RNS, but I think the below just about edges it for me; "Securing a contract requires an application and rigorous review against specific criteria, including the status of the provider, the quality and dependability of the service provided, and the need for the testing service." The last line in particular, about the need for the service is absolutely key. They wouldn't have signed a contract if there wasn't a need. How big is the need? Over 5-10 years you would think it'll be very significant indeed. at $950 a test you only need to run just over 1m tests to generate $1b of revenue... Current forecasts for 2022 are for $42m of revenue, which would require only 44k tests from this contract... As per page 10 of this PDF: there are estimated to be 4.2m federal employees in 2021, but this doesn't include VA, IHS or 'Affiliates around the world'. Even so, we would only need 1% of those 4.2m core employees to use KidneyIntelX in 2022 to hit our forecasts. The sheer scale has taken some time to sink in... Although I'm reluctant to call NASDAQ due to past experiences here, surely it has to fly today? | 74tom | |
22/4/2021 10:39 | Vrci will come alive later this year imho. Potentially great company. CareDX in its crosshairs. | mr roper | |
22/4/2021 10:36 | Just need a similar performance from Verici now. | busterdog2 | |
22/4/2021 10:33 | While volume is much higher than usual, reported trades are around £2m worth. So 0.25% of market cap. Shows how tightly held this is | donald pond | |
22/4/2021 10:29 | Thanks, guys. Have built up a decent stake over the past 3 days. Topped up this morning. | ramridge | |
22/4/2021 10:29 | KidneyIntelX has also been deployed in the Mount Sinai Health System and New York State without FDA approval. However, FDA approval, and one assumes national Medicare coverage, will provide another inflection point in terms of revenue generation. | wan | |
22/4/2021 10:28 | I’m gonna get a few beers in and watch the show lol | mr roper | |
22/4/2021 10:25 | I'm not sure if a US based company with such a low market cap and US float has ever released news on this scale. I would not rule out anything this afternoon | donald pond | |
22/4/2021 10:23 | Dp, I would not be surprised if you were right re 100% day. As I said earlier though, I suspect we’ll have more than 1 in the next 12mths. The doors to the kidney disease diagnostic market have just been blown off. | mr roper | |
22/4/2021 10:21 | Renx already have commercial approval in multiple States without fda. They are revenue generating from last quarter as per the Mt Sinai agreement. Strap yourselves in. Bought a ticket for the big show. | mr roper | |
22/4/2021 10:18 | No renx can condict testing with no fda approval. Fda is just a nice to have for obvious reasons ref opinion and roll out. | nimbo1 | |
22/4/2021 10:09 | Guys - I am trying to get my head around the company getting a massive contract, when the product is still waiting FDA approval. Simply put, is this contract subject to FDA approval being granted in 2021? Genuine question from someone who knows precious little about the pharma world. | ramridge | |
22/4/2021 09:50 | I honestly think there is a good chance of a 100% day in the US today. We've gone from a promising product with no sales or FDA approval to having a 10 year contract with the biggest organisation in the world. That means there has to be a reasonable chance that our best expectations for RENX are not optimistic enough. | donald pond | |
22/4/2021 09:40 | Volume so far is relatively modest at 100k. But the news is absolutely huge. Suggests to me there is a wall of buying yet to come. | someuwin | |
22/4/2021 09:37 | Worth remembering our brokers are Stifel who are top tier in the US. | donald pond | |
22/4/2021 09:27 | very significant news today but only those who are investors or have been following RENX very closely will initially realise this. If you just had a passing interest, such a contract for a $750m company would be mehhh and that my friends is the pool of investors/traders where we're going to start getting attention from now. Once US market opens I am confident we will be comfortably above previous ATH's but I ain't got a clue how to value such a big contract so lets wait for the brokers to play catch up GLAH @mginvestor | mginvestor | |
22/4/2021 09:16 | 74tom...I think we could end up with too much in the header ;-) And today's news will effectively demonstrate how quickly things can change, given the track record of effective execution by the management team, who are also clearly delivering in terms of expanding the multiple revenue pathways from KidneyIntelX testing sales, pharma driven development programs and other strategic partnership initiatives e.g. their recently announced partnership with DaVita (NASDAQ DVA). | wan | |
22/4/2021 09:10 | ...Kidney is the new Cancer. | someuwin | |
22/4/2021 09:01 | Seems like a good time to repost this excellent interview from Feb, first posted by mginvestor.... - possibly one for the header @Wan? The 'things could get very big, very quick' line has been illustrated today... | 74tom | |
22/4/2021 08:43 | I don't usually add to a share where I'm 100% up but I've made an exception today | danieldruff2 | |
22/4/2021 08:35 | Although I have put the KidneyIntelX website in the header, I will highlight it again here with todays news/details - Contact Us For questions or to order KidneyIntelX, please contact our Market Access team: | wan | |
22/4/2021 08:34 | KidneyIntelX is the right kind of disruptive tech. Right place, right time. No competition, a monstrous target market, contracts and partnerships being delivered. If Renx get the execution right and the revenue follows I suspect you could add a zero to today’s stock price on a 24mth view. Would not be surprised to see a 100% day or two here in the next 12mths. | mr roper | |
22/4/2021 08:30 | Fantastic news in all respects. It would seem that this contract had already been agreed and was conditional on results from the recently reported clinical utility studies. The sky is surely the limit now, as Mr Roper said earlier, even a 1% penetration into an 18m target market results in revenues of $171m... | 74tom | |
22/4/2021 08:23 | Well I bought in on the back of that rns. Flare seems pretty visible to me.... | pilkersa |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions